Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Kyu Kim

Rheumatology Boston, MA Medical Doctor

NPI 1942442405 CMS profile 447374

725 Albany St, Ste 8A, Shapiro Bldg, Rheumatology, Boston, MA 02118

Open in the dashboard

General payments

$686

64 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Kyu Kim of Boston, MA is reported in the CMS Open Payments database as having received $686 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $240 1
2020 General $17 1
2019 General $429 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyu Kim
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Kyu Kim were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Kyu Kim Rheumatology median Middle half National median
2019 $429 $744 $153–$2,687 $163
2020 $17 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $240 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Janssen Biotech, Inc. $278 50 payments
  2. AbbVie, Inc. $240 1 payment
  3. Novartis Pharmaceuticals Corporation $148 12 payments
  4. GlaxoSmithKline, LLC. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $447 63 payments
  2. Grant $240 1 payment
Products named General payments · program years 2019–2022
  1. RINVOQ $240 1 payment
  2. SIMPONI ARIA $235 41 payments
  3. COSENTYX $148 12 payments
  4. STELARA $81 17 payments
  5. BENLYSTA $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

3,441

Median for Rheumatology: 1,511

Drug cost

$3,802,761

Median for Rheumatology: $1,139,948

Branded share of claims

34.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 167 $1,182,991
Enbrel Sureclick Etanercept Brand 135 $1,097,317
Taltz Autoinjector Ixekizumab Brand 59 $402,848
Rinvoq Upadacitinib Brand 55 $349,640
Otezla Apremilast Brand 37 $173,468
Orencia Clickject Abatacept Brand 27 $166,756
Actemra Actpen Tocilizumab Brand 34 $102,992
Cosentyx Sensoready (2 Pens) Secukinumab Brand 12 $86,552
Humira(Cf) Adalimumab Brand 12 $78,140
Teriparatide Generic 14 $32,544

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$1,049,765

Of which drugs: $915,906

Medicare patients

417

Average age 73

Services billed

70,895

294 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 33%
Diabetes 25%
Ischemic heart disease 22%
Depression 22%
Chronic kidney disease 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, rituximab, 10 mg J9312 Office 17 4,250 $260,234
Injection, golimumab, 1 mg, for intravenous use J1602 Office 21 13,050 $117,631
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 4,010 $99,836
Injection, denosumab, 1 mg J0897 Office 44 4,440 $90,121
Injection, methylprednisolone acetate, 1 mg J1010 Office 55 4,561 $393
Injection, methylprednisolone acetate, 80 mg J1040 Office 29 36 $146
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 17 577 $128
Infusion, normal saline solution, 250 cc J7050 Office 47 221 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record